Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mel Mann"'
Autor:
Randall A. Oyer, Patricia Hurley, Leigh Boehmer, Suanna Steeby Bruinooge, Kathryn Levit, Nadine Barrett, Al Benson, Lea Ann Bernick, Leslie Byatt, Marjory Charlot, Jennie Crews, Kyle DeLeon, Lola Fashoyin-Aje, Elizabeth Garrett-Mayer, Julie R. Gralow, Sybil Green, Carmen E. Guerra, Leila Hamroun, Claudia M. Hardy, Bridgette Hempstead, Sanford Jeames, Mel Mann, Khalid Matin, Worta McCaskill-Stevens, Janette Merrill, Grzegorz S. Nowakowski, Manali I. Patel, Alice Pressman, Amelie G. Ramirez, Juanita Segura, Barbara Segarra-Vasquez, Jen Hanley Williams, James E. Williams, Karen M. Winkfield, Eddy S. Yang, Victoria Zwicker, Lori J. Pierce
Publikováno v:
Journal of Clinical Oncology. 40:2163-2171
A concerted commitment across research stakeholders is necessary to increase equity, diversity, and inclusion (EDI) and address barriers to cancer clinical trial recruitment and participation. Racial and ethnic diversity among trial participants is k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b451dc6b944f2faba50434a9cebf566a
https://doi.org/10.1200/jco.22.00754
https://doi.org/10.1200/jco.22.00754
Autor:
Kendra L. Sweet, Jorge E. Cortes, Jane F. Apperley, Mel Mann, Michael J. Mauro, Vivian G. Oehler, Cristina Ruiz, Charles A. Schiffer, Lori A. Ehrlich, Gulsum E. Pamuk, Joseph Wynne, Gautam U. Mehta, R. Angelo de Claro, Marc R. Theoret, B. Douglas Smith, Kelly J. Norsworthy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
The FDA has an accelerated approval program for drugs that have been identified as promising treatments for serious conditions when the available data suggest that the benefits outweigh the foreseeable risks. All of the currently available treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc23751589223de30fca3b8ddbee69cc
https://pubmed.ncbi.nlm.nih.gov/36547666
https://pubmed.ncbi.nlm.nih.gov/36547666